Genomic intelligence company Claryx has emerged from stealth with $3.5 million in pre-seed funding to commercialize its advanced infection detection platform for hospitals. The round, led by Outlander VC, will support the company's mission to create a real-time immune system for healthcare facilities. Founded by brothers Kurt and Dirk Hackenberger, Claryx uses proprietary technology to identify and trace outbreaks of hospital-acquired infections before they spread.
Addressing a Critical Healthcare Challenge
Hospital-acquired infections represent a severe and costly problem, affecting approximately one in every 38 patients in the United States on any given day. The financial toll on the healthcare system is staggering, reaching as high as $45 billion annually, with associated deaths surpassing those from car accidents. These infections place a direct financial strain on hospitals, which often absorb the costs and face significant Medicare penalties.
A primary obstacle in combating these infections is the difficulty in identifying the connections between seemingly isolated cases. An outbreak can spread silently across multiple wards without triggering alarms until case counts reach a critical threshold. As a result, infection prevention teams often only confirm and react to outbreaks after they have become large enough to be obvious.
A Genomic Approach to Infection Control
Claryx provides a solution by sequencing the genome of pathogens from patient infections to establish definitive transmission links. This genomic surveillance approach allows hospitals to trace an outbreak to its source, whether it is another patient or an environmental reservoir. The company's breakthrough is a proprietary chemistry developed by co-founder Dirk Hackenberger that reduces a key sequencing cost by over twentyfold, making continuous monitoring affordable.
The company's CloneLink platform integrates this genomic data with a digital twin of the hospital, built from its air, water, and surface samples. By matching infection genomes to this environmental map, the system can pinpoint hidden sources of transmission. This enables a proactive strategy, allowing hospitals to intervene before an outbreak becomes a widespread crisis and confirm their response was effective.
Proven Efficacy and Founder Vision
The technology's efficacy is supported by a two-year study at UPMC Presbyterian, published in Clinical Infectious Diseases. The research demonstrated that real-time genomic surveillance identified 172 otherwise undetected outbreaks and stopped 96% of those that were traced and acted upon. The program yielded a 3.2-fold return on investment while preventing an estimated 62 infections and nearly five deaths.
The company's mission is deeply personal for the Hackenberger brothers, whose grandmother suffered a severe hospital-acquired infection. Kurt Hackenberger, CEO, brings extensive investment experience from The Carlyle Group, while Dirk Hackenberger's PhD focused on the genomics of infectious disease. Their combined expertise provides a powerful foundation for tackling this complex healthcare issue with both scientific rigor and business acumen.
Investor Confidence and Future Outlook
The funding round saw participation from Company Ventures, Boost VC, and Precursor, among others, signaling strong market confidence. "Every building people share is a transmission system running invisibly, and Claryx has made it possible to finally see it," said AJ Smith, Partner at lead investor Outlander VC. This investment underscores the belief in Claryx's potential to expand its intelligence platform beyond hospitals.
"We believe preventable infections are a solvable problem," said Kurt Hackenberger, emphasizing a future where infections are stopped before they can even happen. The company is bolstered by a scientific advisory board featuring experts from Mayo Clinic, Harvard, Yale, and the CDC. With its platform already live in multiple health systems, Claryx is actively working toward this preventative future.
Claryx's launch with significant financial backing and a scientifically validated platform marks a pivotal moment in the ongoing battle against hospital-acquired infections. By making sophisticated genomic intelligence accessible and affordable, the company is poised to transform infection control protocols. This innovation promises not only to enhance patient safety and save lives but also to alleviate the immense financial burden these infections place on healthcare systems.